Things that can go wrong.

The most cited private companies have raised at valuations that imply rapid revenue scale-up. Public companies with material humanoid exposure (Tesla, Hyundai, UBTECH, Foxconn) trade on much broader narratives — humanoid exposure can be inside a fraction of one percent of their business. Either path can disappoint independently of whether the technology works.

Several things that look almost-solved are not. Dexterous manipulation under varied lighting and contact conditions. Long-duration battery life under heavy mechanical load. Reliable autonomy that does not require a human reviewing the feed. These problems may take much longer than current roadmaps imply, and there is no reliable way to know in advance which company will solve them first.

Workplace deployment of humanoids is largely unregulated in most jurisdictions today. That will change. Insurance markets for human-robot collaborative environments are nascent. The first significant incident — injury, property damage, security breach — will shape the regulatory floor, and the floor will likely be higher than current pilot deployments anticipate.

Most humanoid companies are pre-revenue or barely-revenue. The transition from pilot to recurring revenue is the largest single execution risk in the category. Pilots are not commercial customers; press releases are not contracts. The Reality Score on the roster pages is designed to surface this distinction.

A meaningful share of the global humanoid roster is being built in China (Unitree, UBTECH, Fourier, XPeng, and others). Western analyst access to Chinese facilities is limited; export controls and sanctions can shift quickly. Exposure to non-Chinese supply chains has its own concentration risks.

The category is small enough that 'the humanoid trade' barely exists as a tradable thing. Thematic ETFs that claim humanoid exposure typically own broader robotics, automation, or AI. Pure-play exposure usually means private-market access — which is illiquid, often inaccessible to retail, and concentrated in companies that may not survive.

Closed-end funds and vehicles holding private robotics companies introduce risks beyond the robotics theme itself. Shares can trade at a premium or discount to NAV. Private holdings may be valued using fair-value procedures rather than live market prices. Fees, leverage, portfolio concentration, lockups, and manager discretion can matter more than the headline list of robotics companies.

This site is editorial. Our Reality Score is a judgment call documented in the methodology, not an objective metric. Read the rubric on the /about page. Treat our coverage as one input, not a recommendation, and be skeptical of any source — including this one — that gives you a tidy answer to a question that is genuinely open.